Request Free Sample
×
PD 1 Non Small Cell Lung Cancer Treatment Market
ID: MRFR/HC/35143-HCR
100 Pages
October 2025
PD-1 Rapport d’étude de marché sur le traitement du cancer du poumon non à petites cellules par type de médicament (anticorps monoclonaux, thérapie combinée, inhibiteurs de points de contrôle), par voie d’administration (intraveineuse, orale, sous-cutanée), par phase de traitement (thérapie adjuvante, thérapie néoadjuvante, soins palliatifs), par utilisateur final (hôpitaux, cliniques spécialisées, centres de chirurgie ambulatoire) et par région (Amérique du Nord, Europe, Amérique du Sud, Asie-Pacifique, Moyen-Orient et Afrique) – Prévisions pour 2034
Les principales entreprises du marché PD 1 Non Small Cell Lung Cancer Treatment Market incluent
Portée du rapport
Laisser un commentaire
FAQs
What is the projected market valuation for the PD-1 Non-Small Cell Lung Cancer Treatment Market in 2035?
The projected market valuation for the PD-1 Non-Small Cell Lung Cancer Treatment Market in 2035 is 57.8 USD Billion.
What was the market valuation for the PD-1 Non-Small Cell Lung Cancer Treatment Market in 2024?
The market valuation for the PD-1 Non-Small Cell Lung Cancer Treatment Market in 2024 was 29.09 USD Billion.
What is the expected CAGR for the PD-1 Non-Small Cell Lung Cancer Treatment Market from 2025 to 2035?
The expected CAGR for the PD-1 Non-Small Cell Lung Cancer Treatment Market during the forecast period 2025 - 2035 is 6.44%.
Which companies are considered key players in the PD-1 Non-Small Cell Lung Cancer Treatment Market?
Key players in the market include Bristol-Myers Squibb, Merck & Co., Roche, AstraZeneca, Novartis, Pfizer, Eli Lilly and Company, Regeneron Pharmaceuticals, and Boehringer Ingelheim.
What are the main segments of the PD-1 Non-Small Cell Lung Cancer Treatment Market?
The main segments of the market include Type, Administration Route, Treatment Phase, and End User.
What was the valuation of the Monoclonal Antibodies segment in 2024?
The valuation of the Monoclonal Antibodies segment in 2024 was 10.0 USD Billion.
What is the projected valuation for the Combination Therapy segment by 2035?
The projected valuation for the Combination Therapy segment by 2035 is 15.0 USD Billion.
How does the valuation of the Palliative Care segment compare to other treatment phases?
The valuation of the Palliative Care segment in 2024 was 11.09 USD Billion, indicating a competitive position among treatment phases.
What is the expected growth for the Subcutaneous administration route by 2035?
The expected growth for the Subcutaneous administration route is projected to reach 22.8 USD Billion by 2035.
Which end user segment is anticipated to have the highest valuation in 2035?
The Ambulatory Surgical Centers end user segment is anticipated to have the highest valuation, projected at 22.8 USD Billion by 2035.
Télécharger l'échantillon gratuit
Veuillez remplir le formulaire ci-dessous pour recevoir un échantillon gratuit de ce rapport
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
Étude de cas
Aerospace & Defense